As shown in Figure 8A–8D, HCC patients with high APEX1 expression were associated with worse overall survival (OS, log-rank p=0.017), disease-specific survival (DSS, log-rank p=0.075), progression-free survival (PFS, log-rank p=0.006), and relapse-free survival (RFS, log-rank p=0.0011). This evidence concerns the gene APEX1 and hepatocellular carcinoma.